Anika Therapeutics Q3 Earnings Outperform Estimates, Shares Down 41.5% YTD

Anika Therapeutics (ANIK) reported Q3 earnings of $0.04 per share, beating estimates by $0.02 per share. Revenues were $27.82 million, surpassing the Zacks Consensus Estimate by 0.06%. The company has topped consensus revenue estimates three times over the last four quarters. Anika shares have lost 41.5% since the beginning of the year versus the S&P 500's gain of 15.1%.